A screen for and validation of prodrug antimicrobials

Laura E. Fleck, E. Jeffrey North, Richard E. Lee, Lawrence R. Mulcahy, Gabriele Casadei, Kim Lewis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The rise of resistant pathogens and chronic infections tolerant to antibiotics presents an unmet need for novel antimicrobial compounds. Identifying broad-spectrum leads is challenging due to the effective penetration barrier of Gram-negative bacteria, formed by an outer membrane restricting amphipathic compounds, and multidrug resistance (MDR) pumps. In chronic infections, pathogens are shielded from the immune system by biofilms or host cells, and dormant persisters tolerant to antibiotics are responsible for recalcitrance to chemotherapy with conventional antibiotics. We reasoned that the dual need for broad-spectrum and sterilizing compounds could be met by developing prodrugs that are activated by bacterium-specific enzymes and that these generally reactive compounds could kill persisters and accumulate over time due to irreversible binding to targets. We report the development of a screen for prodrugs, based on identifying compounds that nonspecifically inhibit reduction of the viability dye alamarBlue, and then eliminate generally toxic compounds by testing for cytotoxicity. A large pilot of 55,000 compounds against Escherichia coli produced 20 hits, 3 of which were further examined. One compound, ADC111, is an analog of a known nitrofuran prodrug nitrofurantoin, and its activity depends on the presence of activating enzymes nitroreductases. ADC112 is an analog of another known antimicrobial tilbroquinol with unknown mechanism of action, and ADC113 does not belong to an approved class. All three compounds had a good spectrum and showed good to excellent activity against persister cells in biofilm and stationary cultures. These results suggest that screening for overlooked prodrugs may present a viable platform for antimicrobial discovery.

Original languageEnglish
Pages (from-to)1410-1419
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number3
DOIs
StatePublished - Mar 2014
Externally publishedYes

Fingerprint

Prodrugs
Biofilms
Anti-Bacterial Agents
Nitroreductases
Nitrofurans
Nitrofurantoin
Poisons
Multiple Drug Resistance
Enzymes
Infection
Gram-Negative Bacteria
Immune System
Coloring Agents
Escherichia coli
Bacteria
Drug Therapy
Membranes

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Fleck, L. E., North, E. J., Lee, R. E., Mulcahy, L. R., Casadei, G., & Lewis, K. (2014). A screen for and validation of prodrug antimicrobials. Antimicrobial Agents and Chemotherapy, 58(3), 1410-1419. https://doi.org/10.1128/AAC.02136-13

A screen for and validation of prodrug antimicrobials. / Fleck, Laura E.; North, E. Jeffrey; Lee, Richard E.; Mulcahy, Lawrence R.; Casadei, Gabriele; Lewis, Kim.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 3, 03.2014, p. 1410-1419.

Research output: Contribution to journalArticle

Fleck, LE, North, EJ, Lee, RE, Mulcahy, LR, Casadei, G & Lewis, K 2014, 'A screen for and validation of prodrug antimicrobials', Antimicrobial Agents and Chemotherapy, vol. 58, no. 3, pp. 1410-1419. https://doi.org/10.1128/AAC.02136-13
Fleck, Laura E. ; North, E. Jeffrey ; Lee, Richard E. ; Mulcahy, Lawrence R. ; Casadei, Gabriele ; Lewis, Kim. / A screen for and validation of prodrug antimicrobials. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 3. pp. 1410-1419.
@article{02b87aa5e3564c76bb03b9a9ce83d283,
title = "A screen for and validation of prodrug antimicrobials",
abstract = "The rise of resistant pathogens and chronic infections tolerant to antibiotics presents an unmet need for novel antimicrobial compounds. Identifying broad-spectrum leads is challenging due to the effective penetration barrier of Gram-negative bacteria, formed by an outer membrane restricting amphipathic compounds, and multidrug resistance (MDR) pumps. In chronic infections, pathogens are shielded from the immune system by biofilms or host cells, and dormant persisters tolerant to antibiotics are responsible for recalcitrance to chemotherapy with conventional antibiotics. We reasoned that the dual need for broad-spectrum and sterilizing compounds could be met by developing prodrugs that are activated by bacterium-specific enzymes and that these generally reactive compounds could kill persisters and accumulate over time due to irreversible binding to targets. We report the development of a screen for prodrugs, based on identifying compounds that nonspecifically inhibit reduction of the viability dye alamarBlue, and then eliminate generally toxic compounds by testing for cytotoxicity. A large pilot of 55,000 compounds against Escherichia coli produced 20 hits, 3 of which were further examined. One compound, ADC111, is an analog of a known nitrofuran prodrug nitrofurantoin, and its activity depends on the presence of activating enzymes nitroreductases. ADC112 is an analog of another known antimicrobial tilbroquinol with unknown mechanism of action, and ADC113 does not belong to an approved class. All three compounds had a good spectrum and showed good to excellent activity against persister cells in biofilm and stationary cultures. These results suggest that screening for overlooked prodrugs may present a viable platform for antimicrobial discovery.",
author = "Fleck, {Laura E.} and North, {E. Jeffrey} and Lee, {Richard E.} and Mulcahy, {Lawrence R.} and Gabriele Casadei and Kim Lewis",
year = "2014",
month = "3",
doi = "10.1128/AAC.02136-13",
language = "English",
volume = "58",
pages = "1410--1419",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - A screen for and validation of prodrug antimicrobials

AU - Fleck, Laura E.

AU - North, E. Jeffrey

AU - Lee, Richard E.

AU - Mulcahy, Lawrence R.

AU - Casadei, Gabriele

AU - Lewis, Kim

PY - 2014/3

Y1 - 2014/3

N2 - The rise of resistant pathogens and chronic infections tolerant to antibiotics presents an unmet need for novel antimicrobial compounds. Identifying broad-spectrum leads is challenging due to the effective penetration barrier of Gram-negative bacteria, formed by an outer membrane restricting amphipathic compounds, and multidrug resistance (MDR) pumps. In chronic infections, pathogens are shielded from the immune system by biofilms or host cells, and dormant persisters tolerant to antibiotics are responsible for recalcitrance to chemotherapy with conventional antibiotics. We reasoned that the dual need for broad-spectrum and sterilizing compounds could be met by developing prodrugs that are activated by bacterium-specific enzymes and that these generally reactive compounds could kill persisters and accumulate over time due to irreversible binding to targets. We report the development of a screen for prodrugs, based on identifying compounds that nonspecifically inhibit reduction of the viability dye alamarBlue, and then eliminate generally toxic compounds by testing for cytotoxicity. A large pilot of 55,000 compounds against Escherichia coli produced 20 hits, 3 of which were further examined. One compound, ADC111, is an analog of a known nitrofuran prodrug nitrofurantoin, and its activity depends on the presence of activating enzymes nitroreductases. ADC112 is an analog of another known antimicrobial tilbroquinol with unknown mechanism of action, and ADC113 does not belong to an approved class. All three compounds had a good spectrum and showed good to excellent activity against persister cells in biofilm and stationary cultures. These results suggest that screening for overlooked prodrugs may present a viable platform for antimicrobial discovery.

AB - The rise of resistant pathogens and chronic infections tolerant to antibiotics presents an unmet need for novel antimicrobial compounds. Identifying broad-spectrum leads is challenging due to the effective penetration barrier of Gram-negative bacteria, formed by an outer membrane restricting amphipathic compounds, and multidrug resistance (MDR) pumps. In chronic infections, pathogens are shielded from the immune system by biofilms or host cells, and dormant persisters tolerant to antibiotics are responsible for recalcitrance to chemotherapy with conventional antibiotics. We reasoned that the dual need for broad-spectrum and sterilizing compounds could be met by developing prodrugs that are activated by bacterium-specific enzymes and that these generally reactive compounds could kill persisters and accumulate over time due to irreversible binding to targets. We report the development of a screen for prodrugs, based on identifying compounds that nonspecifically inhibit reduction of the viability dye alamarBlue, and then eliminate generally toxic compounds by testing for cytotoxicity. A large pilot of 55,000 compounds against Escherichia coli produced 20 hits, 3 of which were further examined. One compound, ADC111, is an analog of a known nitrofuran prodrug nitrofurantoin, and its activity depends on the presence of activating enzymes nitroreductases. ADC112 is an analog of another known antimicrobial tilbroquinol with unknown mechanism of action, and ADC113 does not belong to an approved class. All three compounds had a good spectrum and showed good to excellent activity against persister cells in biofilm and stationary cultures. These results suggest that screening for overlooked prodrugs may present a viable platform for antimicrobial discovery.

UR - http://www.scopus.com/inward/record.url?scp=84896880099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896880099&partnerID=8YFLogxK

U2 - 10.1128/AAC.02136-13

DO - 10.1128/AAC.02136-13

M3 - Article

C2 - 24342644

AN - SCOPUS:84896880099

VL - 58

SP - 1410

EP - 1419

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -